HALO Stock Recent News

Clinical studies in anxiety and insomnia expected to commence in the third quarter of 2024 Clinical studies in anxiety and insomnia expected to commence in the third quarter of 2024

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Updated Prescription Drug User Fee Act goal date of December 29, 2024 SAN DIEGO , May 21, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Bristol Myers Squibb was reassigned a Prescription Drug User Fee Act goal date from the U.S. Food and Drug Administration for their Biologics License Application for the subcutaneous formulation of Opdivo ® (nivolumab) co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, across all previously approved adult, solid tumor Opdivo indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy (ipilimumab) combination therapy, or in combination with chemotherapy or cabozantinib. The updated goal date is December 29, 2024.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Halozyme (HALO) reports mixed first-quarter 2024 earnings. The company maintains revenue guidance for 2024.

SAN DIEGO , May 8, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Nicole LaBrosse, Chief Financial Officer, is scheduled to present and host investor meetings at the following investor conferences: Event: The Citizens JMP Life Sciences Conference Format: Fireside Chat and 1x1 Meetings Presentation Date: Tuesday, May 14, 2024 Presentation Time: 7:00 a.m. PT / 10:00 a.m.

Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Tram Bui - Vice President of Investor Relations and Corporate Communications Helen Torley - President and Chief Executive Officer Nicole LaBrosse - Chief Financial Officer Conference Call Participants Vikram Purohit - Morgan Stanley Jessica Fye - J.P. Morgan Michael DiFiore - Evercore ISI Mohit Bansal - Wells Fargo Corinne Johnson - Goldman Sachs Jason Butler - Citizens JMP Brendan Smith - TD Cowen Mitchell Kapoor - H.C.

The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Halozyme Therapeutics (HALO) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.47 per share a year ago.